Infliximab in ulcerative colitis
Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, place...
Main Authors: | Levin, Avi, Shibolet, Oren |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2008
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721383/ |
Similar Items
-
Promising effect of infliximab on the extent of involvement in ulcerative colitis
by: Adibi, Peyman, et al.
Published: (2011) -
Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update
by: Lawlor, Garrett, et al.
Published: (2009) -
Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab
by: Puthoor, Pamela R., et al.
Published: (2013) -
The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
by: Seo, Hyun Il, et al.
Published: (2014) -
Pediatric ulcerative colitis: current treatment approaches including role of infliximab
by: Bradley, Gia M, et al.
Published: (2012)